Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nyer to acquire minority interest in pharmacy chain subsidiary
By agreeing to a series of transactions, the minority shareholders will immediately assume management of Nyer and will control approximately 58% of the voting power of Nyer. Karen
By agreeing to a series of transactions, the minority shareholders will immediately assume management of Nyer and will control approximately 58% of the voting power of Nyer. Karen
The first patients have been enrolled and have undergone initial treatment steps in preparation for receiving DCVax-L. The trial involves two sequential studies, and comprises an innovative combination
The laboratory developed test performed on a real-time PCR platform to detect Rhesus D (RhD) incompatibility will be marketed by Sequenom’s nonexclusive licensee, CLIA-certified, Lenetix Medical Screening Laboratory
Mr. Karr has entered into a consulting agreement with the company and will remain a member of the company’s board of directors. Mr. Karr said: “I am proud
Stephen Seiler has resigned as president and CEO of the company for health reasons. Mr. Seiler has also resigned from the board of directors. Mr. Davis said: “I
Under the agreement all of the company’s outstanding shares of common stock (other than shares of common stock held by Eisai or its subsidiaries or by stockholders who
Cell Therapeutics (CTI) made an initial payment of $10 million to Biogen Idec in exchange for control of US marketing, sales, and development of Zevalin. Under the terms
Proton Beam therapy is a new and remarkable type of cancer treatment that minimizes the unnecessary irradiation to the normal tissue compared with conventional electron beam and x-ray
Varian is acquiring the privately held business for approximately $2 million in cash plus an additional amount based on achievement of specified milestones. Pan-Pacific Enterprises, which has approximately
The agreement also grants Top Care Korea exclusive rights to distribute Exalenz’s BreathID System in Korea. Top Care Korea plans to launch BreathID System in first half of